Study offers new insights into the role of LSECs in NASH development, suggests targeting liver endothelial autophagy as a potential treatment strategy.
Dive into the transformative world of liver health with Prof. Vlad Ratziu's enlightening insights on the latest nomenclature and definitions for steatotic liver disease. Discover why the medical community is adopting a new, inclusive language for Non-Alcoholic Fatty Liver Disease (NAFLD), now redefined to reflect its complex interplay with metabolic dysfunction and lifestyle factors.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD) has emerged as a leading cause of chronic liver disease, affecting a staggering 30% of the global population.
Explore Prof. Wong's insights on MASLD treatment advancements from AASLD, featuring key drugs like Resmetirom, Lanifibranor, and Semaglutide with a focus on Lanifibranor
Despite its health complications and inherent intra- and inter-observer variability, liver biopsy remains the gold standard for the detection of non-alcoholic steatohepatitis (NASH).